Voyager Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
VYGR$1.99+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 6. EXHIBITS
The exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.
INDEX TO EXHIBITS
| | | | | | | | ||||||
| | | | | Incorporated by Reference to: | | | ||||||
| | | | | | | | ||||||
| ExhibitNo. | Description | Form orSchedule | ExhibitNo. | FilingDate withSEC | SEC FileNumber | FiledHerewith | ||||||
| | | | | | | | ||||||
| 10.1 | | Form of Performance Restricted Stock Unit Award Agreement. | | | | | | | | | X | |
| | | | | | | | | | | | | |
| 10.2 | | Second Amendment to Option and License Agreement, by and between the Company and AstraZeneca Ireland Limited, dated as of March 15, 2025. | | | | | | | | | | X |
| | | | | | | | | | | | | |
| 31.1 | | Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14 or 15d-14. | | | | | | | | | | X |
| | | | | | | | | | | | | |
| 31.2 | | Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14 or 15d-14. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 32.1+ | | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 101.INS | | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 101.SCH | | Inline XBRL Taxonomy Extension Schema Document. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 101.CAL | | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 101.DEF | | Inline XBRL Taxonomy Extension Definition Linkbase Document. | | | | | | | | | | X |
| | | | | | | | | | | | | |
| 101.LAB | | Inline XBRL Taxonomy Extension Label Linkbase Document. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 101.PRE | | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | | | | | | | | | | X |
| | | | | | | | | | | |||
| 104 | | Cover Page Interactive Data File – The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | | | | | | | | | | |
| + | The certification furnished in Exhibit 32.1 hereto is deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.